Literature DB >> 27804916

End-of-life care decisions using a Korean advance directive among cancer patient-caregiver dyads.

Shinmi Kim1, Sujin Koh2, Kwonoh Park3, Jinshil Kim4.   

Abstract

OBJECTIVE: The Korean advance directive (K-AD) comprises a value statement, treatment directives, preferences for cardiopulmonary resuscitation (CPR), artificial ventilation, tube feeding, and hospice care, as well as a proxy appointment. The K-AD can facilitate a patient's decision making with respect to end-of-life (EoL) care. The present study aimed to examine the extent to which patient-caregiver dyads would use the K-AD and agree on EoL care decisions.
METHODS: Using a descriptive study design, 81 cancer patients were invited to participate. The final sample consisted of 44 patient-caregiver dyads who completed survey questionnaires, including the K-AD. One patient did not complete all parts of the questionnaire, and 36 (44.4%) declined to participate. Content analysis was conducted to examine the K-AD value statements. Cohen's kappa coefficient was calculated to determine the degree of patient-caregiver dyadic agreement on K-AD treatment directives (Sudore & Fried, 2010).
RESULTS: Our patient participants had the following cancer diagnoses: colorectal 29.5%, breast 29.5%, and liver/biliary tract cancers, 15.9%. Half of the sample had advanced-stage disease. Spouses (70.5%) or adult children (20.4%) were the primary caregivers, with perceived bonding rated as fair (31.8%) or good (65.9%). Rejection of the K-AD was mainly due to the difficulty involved in deciding on EoL care (50%). Comfort while dying was the most common theme expressed by patients (73.8%) and caregivers (66.7%). In terms of treatment directives, dyads advocated for hospice care (66.7%) and reduced support for aggressive treatments of CPR or artificial ventilation. The use of CPR (κ = 0.43, p = 0.004) and artificial ventilation (κ = 0.28, p = 0.046) showed significantly mild to moderate concordance among the dyads. Some 16 of the 21 dyads identified their spouses as a proxy, with others designating their adult children. SIGNIFICANCE OF
RESULTS: The degree of patient-caregiver concordance on the K-AD seemed applicable, and achieved mild to moderate concordance. Our findings are exploratory but suggest the need for EoL discussions where patient-caregiver dyads are encouraged to participate in EoL care decision making.

Entities:  

Keywords:  Cancer patients; Caregivers; End-of-life decision making; Korean advance directives

Mesh:

Year:  2016        PMID: 27804916     DOI: 10.1017/S1478951516000808

Source DB:  PubMed          Journal:  Palliat Support Care        ISSN: 1478-9515


  5 in total

1.  Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer.

Authors:  Ho Jung An; Hyun Jeong Jeon; Sang Hoon Chun; Hyun Ae Jung; Hee Kyung Ahn; Kyung Hee Lee; Min-Ho Kim; Ju Hee Kim; Jaekyung Cheon; JinShil Kim; Su-Jin Koh
Journal:  Cancer Res Treat       Date:  2019-04-18       Impact factor: 4.679

2.  Attitudes toward advance directives and prognosis in patients with heart failure: a pilot study.

Authors:  JinShil Kim; Minjeong An; Seongkum Heo; Mi-Seung Shin
Journal:  Korean J Intern Med       Date:  2019-02-15       Impact factor: 2.884

3.  Preferences for life-sustaining treatment in Korean adults: a cross-sectional study.

Authors:  HyunChul Youn; Suk-Young Lee; Han-Yong Jung; Shin-Gyeom Kim; Seung-Hyun Kim; Hyun-Ghang Jeong
Journal:  BMJ Open       Date:  2021-01-22       Impact factor: 2.692

4.  Advance Directives and Factors Associated with the Completion in Patients with Heart Failure.

Authors:  JinShil Kim; Mi-Seung Shin; Albert Youngwoo Jang; Shinmi Kim; Seongkum Heo; EunSeok Cha; Minjeong An
Journal:  Int J Environ Res Public Health       Date:  2021-02-12       Impact factor: 3.390

5.  The Impact of Advance Directive Perspectives on the Completion of Life-Sustaining Treatment Decisions in Patients with Heart Failure: A Prospective Study.

Authors:  JinShil Kim; Seongkum Heo; Bong Roung Kim; Soon Yong Suh; Jae Lan Shim; Minjeong An; Mi-Seung Shin
Journal:  J Clin Med       Date:  2021-12-19       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.